|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Men With Low Testosterone Levels | |||||
| 2 | Interventions listed in this trial | ||||
| Testosterone Enanthate | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Methyltestosterone | |||||
| Testosterone | |||||
| Testosterone 17 beta-cypionate | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anabolic Agents | |||||
| Androgens | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Hormonal | |||||
| Hormones | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Urological Sciences Research Foundation | |||||
| Solvay Pharmaceuticals | |||||
| Watson Pharmaceuticals | |||||